Editorially Independent Content Supported by Novartis.

Time for Dermatologists to Reclaim Chronic Spontaneous Urticaria

New therapeutic options, particularly oral BTK inhibition with remibrutinib, have eliminated many of the barriers that once pushed patients with chronic spontaneous urticaria toward allergist

ReachMD Healthcare Image

KEY TAKEAWAYS

  • Dermatologists can effectively diagnose and manage chronic spontaneous urticaria (CSU) without routine referral to allergists, using targeted therapies and streamlined diagnostic approaches that minimize unnecessary allergy testing.
  • Remibrutinib, an oral Bruton tyrosine kinase (BTK) inhibitor, represents a significant advance in CSU treatment by targeting mast cell activation, offering rapid symptom improvement, and eliminating barriers associated with injectable therapies.
  • Current CSU treatment guidelines recommend second-generation H1 antihistamines as first-line therapy, with dose escalation when appropriate and advanced options such as remibrutinib, omalizumab, and dupilumab for patients with inadequately controlled disease.

For years, chronic spontaneous urticaria (CSU) has occupied an unusual position in dermatology. Although its most recognizable manifestations are cutaneous, patients with persistent hives have frequently been referred to allergists for evaluation and treatment. This pattern developed for several reasons, including limited therapeutic options, misconceptions about the underlying disease process, and logistical challenges associated with available treatments.

Today, however, the landscape has changed dramatically. With a better understanding of CSU pathophysiology and the availability of multiple targeted therapies, including the recently approved oral Bruton tyrosine kinase (BTK) inhibitor remibrutinib, dermatologists have an opportunity—and, perhaps, a responsibility—to reclaim the management of this disease.

HOW DERMATOLOGY LOST URTICARIA

The history of CSU management resembles the evolution of treatment for other inflammatory skin diseases. Decades ago, dermatologists often struggled to manage severe psoriasis and hidradenitis suppurativa because effective therapeutic options were limited. As targeted treatments emerged, those conditions became central to dermatologic practice.

CSU followed a different trajectory. For years, antihistamines were the primary treatment option, and patients who failed to respond often remained symptomatic. The introduction of omalizumab represented an important advance, but its administration requirements—in-office administration and observation because of the potential risk of anaphylaxis—created barriers for many dermatology practices.

Meanwhile, patients frequently assumed that their hives must result from an unidentified allergy. This perception reinforced referrals to allergists, and dermatologists gradually relinquished responsibility for a condition that primarily manifests in the skin.

UNDERSTANDING CSU AS AN INFLAMMATORY DISEASE

One of the most important steps toward reclaiming CSU is recognizing that it is not typically an external allergen-driven condition.1

CSU is characterized by recurrent wheals, angioedema, or both for more than 6 weeks without a consistent identifiable external trigger. Mast cell activation is central to its pathophysiology, with histamine release producing the characteristic pruritus and wheals.

The disease is heterogeneous, involving different mechanisms of mast cell activation. These include type I autoallergic pathways involving IgE and type IIb autoimmune mechanisms involving IgG autoantibodies.2

This understanding has important therapeutic implications. Because environmental or dietary triggers are rarely found, dermatologists can focus on controlling the inflammatory pathways responsible for symptoms.

It also means that extensive diagnostic testing is unnecessary for most patients. The international urticaria guidelines recommend only limited routine laboratory testing,1 as a thorough history and physical examination generally provide the information needed to establish the diagnosis. Clinicians should assess medication exposures, symptom duration, associated systemic symptoms, and potential physical triggers.

As in all urticaria, individual wheals typically resolve within 24 hours, although new lesions may continue to appear. Lesions that persist longer, produce pain or burning rather than itching, or resolve with bruising should raise suspicion for urticarial vasculitis and may warrant biopsy.

Physical triggers, including pressure, cold, vibration, and scratching, may suggest chronic inducible urticaria rather than CSU, although the conditions can coexist.

Routine broad contact allergy panels are generally unhelpful. In fact, testing without a clear clinical indication may create unnecessary anxiety when patients receive positive results that do not correspond to clinically meaningful allergies. Limited laboratory evaluation may be appropriate based on the history, examination, and guideline recommendations.

A MORE PRACTICAL TREATMENT ALGORITHM

Second-generation H1 antihistamines remain the foundation of initial CSU treatment. However, their use requires an approach that differs from how patients typically take over-the-counter allergy medications.

Patients should understand that antihistamines are intended to prevent symptoms rather than simply relieve an established flare. Consistent daily dosing is essential.

For patients who do not achieve adequate control with standard dosing, current treatment approaches support increasing the dose of a second-generation H1 antihistamine up to fourfold, when appropriate.1 This strategy can provide meaningful improvement for some patients, although sedation and other tolerability concerns may emerge even with medications generally considered nonsedating.

Antihistamine treatment should not become an indefinite exercise in dose escalation when patients remain symptomatic.

A therapeutic trial of approximately 2-4 weeks, with reassessment of response, can help identify patients who need additional treatment. Documentation of persistent wheals, pruritus, sleep disruption, functional impairment, and inadequate response to antihistamines can also support access to advanced therapies.

Newer targeted therapies approved by the US Food and Drug Administration (FDA) are omalizumab, dupilumab, and remibrutinib.

THE ADVANCED OPTIONS

Of the recent developments in CSU management, the introduction of remibrutinib may be particularly consequential for dermatologists.

Remibrutinib is an oral BTK inhibitor that targets intracellular signaling involved in mast cell and basophil activation. By inhibiting BTK, the medication interferes with signaling downstream of receptors involved in inflammatory mediator release, including histamine.3

This mechanism distinguishes remibrutinib from conventional antihistamines, which block the effects of histamine after its release. Instead, BTK inhibition acts upstream to reduce activation of the cells responsible for producing symptoms.

The clinical implications are significant.

First, remibrutinib offers an oral alternative to injectable targeted therapies such as dupilumab and omalizumab. For patients reluctant to receive regular injections, this represents a meaningful expansion of treatment choice.

Second, it does not require the routine laboratory monitoring associated with some other kinase inhibitors. This is particularly relevant to dermatologists who may be hesitant to introduce a medication class they associate with more complicated safety monitoring.

Third, remibrutinib offers the potential for rapid symptom improvement.3 For individuals experiencing unpredictable, intensely pruritic eruptions, the possibility of rapid relief is particularly meaningful.

Speed of response may also help address another persistent problem in CSU management: repeated reliance on systemic corticosteroids.

Patients frequently receive prednisone from urgent care or primary care clinicians when symptoms become intolerable. Although corticosteroids may temporarily suppress symptoms, repeated or prolonged use carries substantial risks and is not an appropriate long-term management strategy.1

A rapidly acting, targeted oral therapy offers an opportunity to establish sustainable disease control without perpetuating cycles of corticosteroid treatment.

Of course, omalizumab remains an effective option with an established history in CSU.

Dupilumab, meanwhile, offers a familiar and well-established treatment approach for dermatologists, and it can be particularly useful when patients have relevant coexisting type 2 inflammatory diseases, such as atopic dermatitis.4

As with any systemic therapy, treatment selection should account for the prescribing information, individual risk factors, comorbidities, and patient preferences.

TREATING MORE THAN HIVES

Reclaiming CSU also requires dermatologists to recognize the substantial burden of disease beyond visible wheals.

Patients frequently experience sleep disruption, impaired concentration, reduced productivity, and significant anxiety related to the unpredictable nature of their symptoms.5

A patient may worry about developing facial hives during an important professional meeting or experiencing a severe flare while traveling. Even when individual lesions resolve within hours, the uncertainty surrounding their recurrence can profoundly affect quality of life.

These concerns should be incorporated into clinical assessment and treatment decisions.

Patients with persistent symptoms despite appropriately escalated antihistamine therapy should not be expected to tolerate ongoing disruption simply because their condition is not medically life-threatening.

The goal should be sustained disease control, with treatment adjusted according to response and the patient's individual circumstances.

BRINGING CSU BACK TO DERMATOLOGY

Dermatologists have already demonstrated their ability to transform care for complex inflammatory diseases. Psoriasis, atopic dermatitis, and hidradenitis suppurativa have all benefited from expanding therapeutic options and greater physician familiarity with targeted treatments.

CSU should follow the same path.

Its diagnosis is generally straightforward, its evaluation rarely requires extensive testing, and its treatment options have expanded substantially. The introduction of remibrutinib, in particular, addresses several historical barriers by providing an effective oral therapy that can be incorporated into routine dermatology practice.

This is not an argument against collaboration with allergists. Patients with suspected immediate hypersensitivity, atypical presentations, or other conditions requiring specialized evaluation will continue to benefit from multidisciplinary care.

Rather, it is a recognition that uncomplicated CSU does not routinely require referral away from dermatology.

We have the clinical expertise to diagnose this disease, understand its inflammatory mechanisms, evaluate its impact on patients, and select among effective targeted therapies.

Most importantly, we now have the tools to make patients better.

CSU is a disease that manifests primarily in the skin. It belongs within the scope of dermatologic care, and there has never been a better time for dermatologists to take ownership of its management.

Disclosures: The authors were paid honoraria by Practical Dermatology to participate in a video roundtable discussion on this topic.

Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Register

We're glad to see you're enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free